



23rd International Conference on Brain Tumor Research and Therapy

March 26 - 29, 2023

**The Sanctuary at Kiawah
Island, South Carolina**

Hosted by
**The Preston Robert Tisch
Brain Tumor Center at
Duke University**

CONTENT

Sponsors

Committees

Access

Program at Glance

Social Program

Program

Delegates List



Thank you to Our Sponsors

Hosting Sponsor



The Preston Robert Tisch
Brain Tumor Center

Platinum

novocure®

Silver



Brain Tumor
Center



The Arthur and Sonia Labatt
Brain Tumour Research Centre



vimana



ONO PHARMA USA, INC.

CNS
PHARMACEUTICALS

Bronze



*Funding tomorrow's
research today*

Committees

Conference Chair

David Ashley

Steering Committee

Mitchel Berger

Rolf Bjerkvig

Darell Bigner

Masao Matsutani

Ryo Nishikawa

Russel Pieper

James Rutka

John Sampson

Manfred Westphal

Duke Scientific Committee

Annick Desjardins

Peter Fecci

Matthias Gromeier

Mustafa Khasraw

Kyle Walsh

Scientific Review Committee

Daniel Brat

Priscilla Brastianos

Pim French

Frank Furnari

Cynthia Hawkins

Monika Hegi

Jason Huse

Mustafa Khasraw

Michael Lim

Hrvoje Miletic

Patrick Roth

Michael Vogelbaum

Manfred Westphal

Organizing Team

Tom Dod

Jenny Edmunds


Victoria Nguyen

Carol Harbers

Access



Access



Program at Glance

Sunday, March 26

2:00 – 6:00 p.m. / Registration at Hospitality Desk

7:00-10:00 p.m. / Welcome Reception on the Grand Lawn, sponsored by Novocure

Monday, March 27

7:00 - 8:00 a.m. / Breakfast in Ocean Room

7:00 – 5:30 p.m. / Registration and Information at Hospitality Desk

8:00 – 12:20 p.m./Sessions in Grand Oaks Ballrooms

12:20 – 1:20 p.m. / Lunch in Ocean Room

1:20 – 5:15 p.m. / Sessions in Grand Oaks Ballrooms

5:15 - 7:00 p.m. / Break

7:00 - 10:00 p.m. / Lowcountry Seafood Dinner Party

Tuesday, March 28

7:00 - 8:00 a.m. / Breakfast in Ocean Room

7:00 – 1:00 p.m. / Registration and Information at Hospitality Desk

8:00 - 1:00 p.m. / Sessions in Grand Oaks Ballrooms

1:00 - 7:00 p.m. / Boxed Lunch in Foyer and Group Activities

7:00 - 10:00 p.m. / Gala in Grand Oaks Ballrooms

7:45 – 8:10 p.m. / Introduction by Mitchel Berger, MD

Darell Bigner, MD, PhD presents “Neuro-Oncology from 1964 to the Present”

Wednesday, March 29

7:00 - 8:00 a.m. / Breakfast

7:00 – 2:00 p.m. / Registration and Information at Hospitality Desk

8:00 - 12:30 p.m. / Sessions in Grand Oaks Ballrooms

12:30 - 1:30 p.m. / Boxed Lunch in Foyer

Social Program

Sunday, March 26, 2023

Welcome Reception

Time: 7:00 – 10:00 p.m.

Location: Grand Lawn

Attire: Casual

Monday, March 27, 2023

Charleston Carriage Tour (For accompanying guests only)

Time: 9:15 – 3:15 p.m.

Location: Meet in front of Sanctuary

Attire: Casual

Seafood Boil at Mingo Point

Time: 7:00 – 10:00 p.m.

Location: Mingo Point

Attire: Casual

Tuesday, March 28, 2023

Middleton Plantation Tour (For accompanying guests only)

Time: 8:15 – 12:00 p.m.

Location: Meet in front of Sanctuary

Attire: Casual

Fort Sumter Tour

Time: 1:00 – 6:00 p.m.

Location: Meet in front of Sanctuary

Attire: Casual

Gala

Time: 7:00 – 10:00 p.m.

Location: Grand Oaks Ballroom

Attire: Business Formal

Program

Monday, March 27, 2023

Joint Keynote Session

Location: Grand Oaks A/B

8:00 – 8:30 a.m. **Opening Remarks**

Moderators: David Ashley and Rolf Bjerkvig

8:30 – 8:45 **Inferring Cell Type and Cell State Composition in Glioblastoma from Bulk DNA Methylation Profiles Using Multi-Omic Single-Cell Analyses**

Dana Silverbush

8:45 – 9:00 **The Germline Single Nucleotide Polymorphism Rs55705857 at 8q24 Interacts with Somatic IDH1 Mutation to Enhance Human Glioma Formation**

Robert Jenkins

9:00 – 9:15 **Discussion**

9:15 – 9:30 **Break**

Session 1

Session 1A: Molecular Models, Biomarkers, and Targets

Location: Grand Oaks A/B

9:30 - 9:35 **Introduction**

Moderators: James Rutka and Frank Furnari

9:35 - 9:42 **Cellular and Molecular Features of Immunotherapy Response Within the Tumor Microenvironment of Leptomeningeal Metastases**

Priscilla Brastianos

9:42 - 9:49 **Overcoming Resistance to Apoptosis in Malignant Glioma**

David Nathanson

9:49 - 9:56 **Carpool: A High-Throughput In Vitro and In Vivo Platform for Therapeutic Screening**

Erik Sulman

9:56 - 10:03 **A Distinct Epigenetic Subtype of IDH-wildtype Glioblastoma Driven by Genomic Haploidization Characterized by Giant Cell Phenotype and Recurrent TP53, NF1, and RB1 Point Mutations**

David Solomon

Monday, March 27, 2023

- 10:03 - 10:10 **Circulating Extracellular Vesicles as Biomarker for Diagnosis, Prognosis and Monitoring in Glioblastoma**
Katrin Lamszus
- 10:10 - 10:17 **Clinical Applicability of Digital PCR-Based Liquid Biopsy for Detecting MYD88 L265P Mutation in Cerebrospinal Fluid in Patients with Primary CNS Lymphoma**
Motoo Nagane
- 10:17 - 10:24 **Differentiation Induction for Targeting Glioblastoma Stemness**
Yiping He
- 10:24 – 10:31 **Engineered Exosomes Carrying Polycistronic MicroRNA for the Treatment of Glioblastoma**
Frederick Lang
- 10:31 – 10:46 **Discussion**

Session 1B: Tumor Immunology and Immunotherapy
Location: Grand Oaks C/D

- 9:30 - 9:35 **Introduction**
Moderators: Manfred Westphal and Robert Prins
- 9:35 - 9:42 **Correlating Immune Response with Outcome to Checkpoint Inhibition in Newly Diagnosed Glioblastoma Treated with Atezolizumab with Radiation and Temozolomide**
John de Groot
- 9:42 - 9:49 **EO2401 (EO) Peptide Immunotherapy for Patients (PTS) with Recurrent Glioblastoma (GB): Phase 1/2 Rosalie Study**
David Reardon
- 9:49 - 9:56 **Dendritic Cell Surveillance of Glioma Through the Brain-Meningeal Lymphatic-Draining Lymph Node Network**
Kristen Batich
- 9:56 - 10:03 **Developing Non-Exhausted Tumor Infiltrating Lymphocytes (TIL) as a Therapy for Glioblastoma**
Mustafa Khasraw
- 10:03 - 10:10 **Eosinophils as Novel Important Modulators of a Favorable Immune-Responsive Tumor-Microenvironment in Glioblastoma**
Christel Herold-Mende
- 10:10 - 10:17 **Epigenetic Remodelling of the Tumor Immune Microenvironment in Mutant IDH 1 Gliomas: Implications for Immune Mediated Therapies**
Maria Castro

- 10:17 - 10:24 **Identification of Tumor-Specific T Cells Following Neoadjuvant Checkpoint Blockade in Recurrent GBM Patients**
Robert Prins
- 10:24 - 10:31 **RRV for Prodrug Activator Gene Therapy of High-Grade Glioma: Lessons Learned and Future Directions from Bedside to Bench**
Noriyuki Kasahara
- 10:31 – 10:38 **Humanized Bi-Specific Antibody Shows Potent Activity in Patient-Derived Xenograft Models of Glioblastoma**
Irina Balyasnikova
- 10:38 -10:53 **Discussion**
- 10:46 – 11:01 **Break**

Session 2

Session 2A: Clinical Trials
Location: Grand Oaks A/B

- 11:01 - 11:06 **Introduction**
Moderators: Rolf Bjerkvig and Uri Tabori
- 11:06 - 11:13 **Myeloablative Versus Non-Myeloablative Consolidative Chemotherapy for Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Results of CALGB 51101 [alliance]**
Tracy Batchelor
- 11:13 - 11:20 **A Phase 0-Triggered Clinical Trial of AZD1390 plus Radiotherapy in Recurrent Glioblastoma Patients**
Nader Sanai
- 11:20 - 11:27 **A Phase 1 Trial of Oncolytic CAN-3110 Increases Lymphocyte Clonotypes in Recurrent High-grade Glioma Correlating with Survival Responses**
E.Antonio Chiocca
- 11:27 - 11:34 **Neoadjuvant Pembrolizumab for Recurrent Glioblastoma has Dichotomous Responses**
Manfred Westphal
- 11:34 - 11:41 **Weekly Intratumoral Infusion of the Solubilised Formulation of Panobinostat (MTX110) via CED in Patients with Recurrent GBM (MAGIC-G1)**
Annick Desjardins
- 11:41 - 11:48 **Efficacy of Local Administration of Alkylating Agent Against Brainstem Gliomas**
Ryuta Saito

Monday, March 27, 2023

- 11:48 - 11:55 **Results of a Phase I Study Treating First Time Recurrent GBM Patients with Anti-LAG-3 and Anti-PD1**
Michael Lim
- 11:55 - 12:02 **The Brain Perioperative Program**
Jim Whittle
- 11:02 - 12: 17 **Discussion**

Session 2B: GBM Modeling and Real-World Data
Location: Grand Oaks C/D

- 11:01 - 11:06 **Introduction**
Moderators: Mitchel Berger and Cassie Kline
- 11:06 - 11:13 **Glioblastoma Remodeling of Neural Circuits in the Human Brain Decreases Survival**
Shawn Hervey-Jumper
- 11:13 - 11:20 **Antimicrobial Agents That Cause Mitochondrial Dysfunction Significantly Inhibit Glioblastoma Cell Growth by Inducing Ferroptosis**
Koji Yoshimoto
- 11:20 - 11:27 **Blood Biomarkers Distinguishing Pseudoprogression from Recurrence in Glioblastoma**
Mitsutoshi Nakada
- 11:27 - 11:34 **Deciphering Human Glioblastoma Invasion Using a Developmental Mature Rat Brain Organoid Model**
Rolf Bjerkvig
- 11:34 - 11:41 **Exploiting Vulnerabilities in Differential Energy Metabolism in Glioblastoma through NAD Targeting**
Vinay Puduvalli
- 11:41 - 11:48 **Identification of Cancer-Associated Fibroblasts in Glioblastoma and Defining Their Pro-Tumoral Effects**
Manish Aghi
- 11:48 - 11:55 **Meta-analysis of Real-World Data for TTFields Therapy in Newly Diagnosed GBM**
Zvi Ram
- 11:55 - 12:02 **Improvements in Survival for Glioblastoma in the Post-Stupp Protocol Era**
Quinn Ostrom
- 11:02 - 12: 17 **Discussion**
- 12:20 – 1:20 **Lunch**

Session 3

Session 3A: Molecular Models and Targets II

Location: Grand Oaks A/B

- | | |
|-------------|--|
| 1:20 - 1:25 | Introduction
Moderators: John Sampson and Priscilla Brastianos |
| 1:25 - 1:32 | CRISPR-Based Knock-In of C528S Mutant XPO1 Confers Selinexor Resistance in GBM Cell Lines
Russ Pieper |
| 1:32 - 1:39 | Suicide Gene Therapy of Tumor Using TK-expressing Stem Cells from Human Exfoliated Deciduous Teeth
Kazuhiko Kurozumi |
| 1:39 - 1:46 | Discovery of Human Glioblastoma Origin-Cells from the Subventricular Zone
Seok-Gu Kang |
| 1:46 - 1:53 | DNA Methylation of the TERT Promoter Associated with Overall Survival in GBM Patients Without TERT Promoter Mutation
Yukihiko Sonoda |
| 1:53 - 2:00 | EGFR and EGFRvIII Coopt Host Defense Pathways, Promoting Progression in Glioblastoma
William Weiss |
| 2:00 - 2:07 | Epigenetic Reactivation of BAI1 Suppresses Tumor Invasion, Recurrence, and Spinal Metastasis in GBM
Erwin Van Meir |
| 2:07 - 2:14 | Evidence for Cytomegalovirus as a Driver of Progression, Resistance and Poor Outcomes in Glioblastoma
Sean Lawler |
| 2:14 – 2:21 | Spatio-Temporal Organization of Brain Tumors: From Oncostreams to Liquid Crystals
Pedro Lowenstein |
| 2:21 - 2:36 | Discussion |

Session 3B: Radiation and Surgery, and Meningiomas

Location: Grand Oaks C/D

- | | |
|-------------|--|
| 1:20 - 1:25 | Introduction
Moderators: Masao Matsutani and Erik Sulman |
|-------------|--|

1:25 - 1:32	Interim Results of Accelerator-Based BNCT, Randomized Cotrolled Trial for Recurrent and Refractory High-Grade Meningiomas Shin-Ichi Miyatake
1:32 - 1:39	Targeted Gene Expression Profiling Predicts Meningioma Outcomes and Radiotherapy Responses David Raleigh
1:39 - 1:46	Hyper Smart Cyber Operating Theater to Perform Future Predictive Surgery Takashi Komori
1:46 - 1:53	Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma Mitchel Berger
1:53 - 2:00	Molecular Biopsy of the Macro Metastasis / Brain Parenchyma Interface Nils Ole Schmidt
2:00 - 2:07	Preliminary Results of a Prospective Trial of Feasibility and Safety of Using Advanced Intraoperative MRI (iMRI) for Glioma Surgery Randy Jensen
2:07 - 2:14	Rapid Molecular Diagnostics and CNS Neoplasms Daniel Cahill
2:14 - 2:21	US Registered Clinical Trials in Neuro-Oncology: Failure Trends Over Two Decades Isabella Germano
2:21 - 2:36	Discussion
2:36 – 2:51	Break

Session 4

Session 4A: Pathology
Location: Grand Oaks A/B

2:51 - 2:56	Introduction Moderators: Ryo Nishikawa and Giselle Lopez
2:56 - 3:03	A Practical Implementation of Methylation Classification in the Central Diagnostic Review of Pediatric Brain Tumors Koichi Ichimura
3:03 - 3:10	Targeting the Angio-Immune Phenotype in Malignant Brain Tumors Karl H Plate

- 3:10 - 3:17 **Clinicopathologic Analysis of Novel IDH-Wildtype Cerebral and Posterior Fossa Diffuse High-Grade Gliomas**
MacLean Nasrallah
- 3:17 - 3:24 **Giant Cell Glioblastoma does not Represent a Distinct Entity but Stratifies into Different Genetically Defined Entities**
Torsten Pietsch
- 3:24 - 3:31 **Impact of Methylation-Based Diagnostics on WHO 2021 Brain Tumor Classification**
Andreas von Deimling
- 3:31 - 3:38 **Intraoperative Flow Cytometry Predicts CDKN2A/B Homozygous Deletion in “Astrocytoma, IDH-mutant”**
Takashi Komori
- 3:38 - 3:45 **Methylation Profiling and Genomic Analyses of 369 Cases of Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype Characterizes Relevant Subtypes in Children and Adults**
Kenneth Aldape
- 3:45 - 3:52 **Prognostic Significance of TERT Promoter Mutations in CNS WHO Grade 2-3 Adult-type Diffuse Gliomas**
Hideyuki Arita
- 3:52 – 3:59 **Protein and Transcriptomics of Hypercellular Nodules in Oligodendroglioma**
Giselle Lopez
- 3:59 – 4:14 **Discussion**

Session 4B: Pediatrics and Germ Cell Tumors
Location: Grand Oaks C/D

- 2:51 - 2:56 **Introduction**
Moderators: Russel Pieper and David Ashley
- 2:56 - 3:03 **Combining c-MET Inhibition with Radiation is Effective in MET-Fusion Driven High-Grade Glioma**
Marc Zuckermann
- 3:03 - 3:10 **Diagnostic Equivalence of Centralized Immunohistochemistry, Oncoscan™, Nanostring and Methylation Profiling in the Identification of Good-Risk SHH Medulloblastoma: Report of the NEXT/Head Start-4 Prospective International Trial**
Jonathan Finlay
- 3:10 - 3:17 **Pathogenesis of Central Nervous System Germ Cell Tumors Elucidated by Transcriptome and Methylome Analyses**
Hirokazu Takami

- 3:17 - 3:24 **Report on 20-Year Follow-Up Results of a Phase II Trial of Pathology-Based Three-Group Treatment Stratification for Patients with CNS Germ Cell Tumors in Japan**
Masao Matsutani
- 3:24 - 3:31 **Reversal of Cancer Gene Expression Identifies Repurposed Drugs for Diffuse Intrinsic Pontine Glioma**
Theodore Nicolaides
- 3:31 - 3:38 **Self-Reported Race and Ethnicity and Genetic Ancestry Groups Show Distinct Prevalence and Outcomes Across Pediatric Central Nervous System Tumors**
Cassie Kline
- 3:38 - 3:45 **Outcomes of Infants and Young Children with Newly Diagnosed Shh Medulloblastoma Treated on the Next Consortium “Head Start” 4 Protocol**
Girish Dhall
- 3:45 - 4:07 **Discussion**
- 4:07 – 4:22 **Break**

Joint Keynote Session

Location: Grand Oaks A/B

- 4:22 - 4:27 **Introduction**
Moderators: David Ashley and Andreas von Deimling
- 4:27 - 4:42 **Unravel the Complexities of Glioma Evolution Through Spatially Resolved Technologies**
Dieter Henrik Heiland
- 4:42 - 4:57 **Seq-ing the SINEs of Central Nervous System Tumors in Cerebrospinal Fluid DNA**
Chetan Bettgowda
- 4:57 - 5:12 **Discussion**

Program

Tuesday, March 28, 2023

Joint Keynote Session

Location: Grand Oaks A/B

8:00 – 8:30 a.m. **Introduction and Highlights of Previous Day**

Moderators: David Ashley and Mitchel Berger

8:30 – 8:45 **Development and Approval of Oncolytic Herpes Virus G47 Δ Malignant Glioma in Japan**

Tomoki Todo

8:45 – 9:00 **Integrative Multi-Omics Networks Identify Master Kinases of Glioblastoma Subtypes and Guide Targeted Cancer Therapy**

Antonio Iavarone

9:00 – 9:15 **Discussion**

9:15 – 9:30 **Break**

Session 1

Session 1A: Molecular Modeling

Location: Grand Oaks A/B

9:30 – 9:35 **Introduction**

Moderators: Kyle Walsh and Frank Furnari

9:35 – 9:42 **Evolution of Glioblastoma Transcriptomes Reveals Changes in Bulk Composition and a Prognostic Association with Pericyte Expressed Extracellular Matrix**

Pim French

9:42 – 9:49 **Genome-Wide Association Study of Intracranial Germ Cell Tumors**

Keita Terashima

9:49 - 9:56 **Identification of Multi-Target Therapies Against Glioblastoma**

Bart Westerman

9:56 - 10:03 **Mechanisms of Resistance in GBM: Targeting MGMT and EGFR/MEK Signaling for Therapeutic Benefit**

W. K. Alfred Yung

10:03 - 10:10 **Modeling Tert Promoter Mutation in Isogenic GBM Avatar Models**

Frank Furnari

Tuesday, March 28, 2023

- 10:10 - 10:17 **Oncogenic Long Non-Coding RNA LINC02283 Enhances PDGF Receptor A Mediated Signaling and Drives Glioblastoma Tumorigenesis**
Shiyuan Cheng
- 10:17 - 10:24 **Opposing Dysregulation of a Common Set of Genes in H3-G34R and H3-K27M Gliomas Associated with PRC2 Activity and Stalled Differentiation**
Masashi Nomura
- 10:24 - 10:31 **Whole-Genome Sequencing Analysis of Adult Gliomas**
Hiromichi Suzuki
- 10:31 - 10:46 **Discussion**

Session 1B: Imaging
Location: Grand Oaks C/D

- 9:30 - 9:35 **Introduction**
Moderators: Annick Desjardins and Benjamin Ellingson
- 9:35 - 9:42 **Advanced Magnetic Resonance Diffusion Tensor Imaging from BMX-HGG-001 Phase II Clinical Trial: Preliminary Results**
Katherine Peters
- 9:42 - 9:49 **Depth of Response (DpR) and Time to Tumor Regrowth (TTG) Predicts Overall Survival in Recurrent Glioblastoma Treated with Anti-VEGF Therapy**
Benjamin Ellingson
- 9:49 - 9:56 **Detecting Dynamic Pyruvate Tumor Metabolism in Patients with Glioma Using Hyperpolarized Carbon-13 Metabolic Imaging**
Susan Chang
- 9:56 - 10:03 **The Presence of T2-FLAIR Mismatch Sign for Astrocytoma, IDH-Mutant is Influenced by the FLAIR Acquisition Parameter**
Manabu Kinoshita
- 10:03 - 10:10 **Toward a Theranostic Device for Gliomas**
Rachel Grossman
- 10:10 - 10:17 **Towards Predicting Tumor Pathology with Multi-Parametric Anatomical, Physiological, and Metabolic MRI And AI in Patients with Glioma**
Janine Lupo
- 10:17 - 10:24 **RANO 2.0**
Patrick Wen

- 10:24 - 10:31 **Treatment of Diffuse Intrinsic Pontine Glioma Using Doxorubicin and MR-Guided Focused Ultrasound: Preliminary Patient Results from a Phase I Clinical Trial**
James Rutka
- 10:31 - 10:46 **Discussion**
- 10:46 – 11:01 **Break**

Session 2

Session 2A: Clinical Trials GBM and Brain Mets Location: Grand Oaks A/B

- 11:01 - 11:06 **Introduction**
Moderators: Mustafa Khasraw and Adrienne Boire
- 11:06 - 11:13 **Phase I/II Study of Maintenance Therapy with Metformin and Temozolomide for Glioblastoma**
Yoshitaka Narita
- 11:13 - 11:20 **Phase II Study of Bevacizumab Beyond Progression for Patients with Newly Diagnosed Glioblastoma (Biomark): Safety, Efficacy, and Prospective Biomarker Analysis**
Ryo Nishikawa
- 11:20 - 11:27 **Quantifying Tumor Metabolic Impact in Patients with EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR with Brain Penetrant Small Molecule Inhibitors**
Timothy Cloughesy
- 11:27 - 11:34 **Therapeutic Potential of Antibody-Drug Conjugate (ADC) Against Glioblastoma with FGFR3-TACC3 Fusion**
Do-Hyun Nam
- 11:34 - 11:41 **The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCS) of Patients with Leptomeningeal Disease from Systemic Solid Tumor Cancer**
Priya Kumthekar
- 11:41 - 11:48 **The Combination of a Novel RAF/MEK Clamp (avutometinib, VS-6766) and FAK Inhibitor (defactinib, VS-6063) Overcomes MAPK Pathway Inhibitor Resistance in Melanoma Brain Metastases**
Howard Colman
- 11:48 - 11:55 **Inhibition of Tumor-Derived miR-146a-5p Decreases Progression of Melanoma Brain Metastasis in Vitro and in Vivo**
Frits Thorsen

11:55 – 12:02 **A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion**
Macarena de la Fuente

12:02 – 12:17 **Discussion**

Session 2B: Low Grade Gliomas
Location: Grand Oaks C/D

11:01 - 11:06 **Introduction**
Moderators: Samuel McBrayer and Katherine Peters

11:06 - 11:13 **Modeling the Dynamics of IDH Mutant Glioma Initiation**
Samuel McBrayer

11:13 - 11:20 **Patient Derived Brain Tumor Xenografts Models - A Platform for Translational Research**
Steve Keir

11:20 - 11:27 **Postoperative Risk of IDH Mutant Glioma-Associated Seizures and Their Potential Management with IDH Mutant Inhibitors**
Craig Horbinski

11:27 - 11:34 **Quality of Life in Adults with Low Grade Glioma**
Elizabeth Claus

11:34 - 11:41 **Immune Profiles of Lower Grade Adult Glioma Patients**
Stephen Francis

11:41 - 11:48 **Understanding Therapeutic Sensitivity and the Role of Senescence in Pediatric Low-Grade Gliomas**
Charles Eberhart

11:48 - 11:55 **Single-Cell Profiling Establishes Tumor Mutation as a Driver of Local and Systemic Myeloid Cell Identity in Astrocytomas and Oligodendrogliomas**
Vidyalakshmi Chandramohan

11:55 - 12:02 **The Role of Active and Passive DNA Demethylation During the Malignant Progression of IDH-Mutant Low-Grade Glioma**
Akitake Mukasa

12:02 – 12:17 **Discussion**

12:20 – 1:20 **Lunch in Foyer**

Program

Wednesday, March 29, 2023

Joint Keynote Session

Location: Grand Oaks A/B

8:00 – 8:30 a.m. Introduction and Highlights of Previous Day

Moderators: David Ashley and Koichi Ichimura

8:30 - 8:45 **Regulating the Glioma Immune Microenvironment**

Joanna Phillips

8:45 - 9:00 **A Novel MHC-Independent Mechanism of Tumor Cell Killing by CD8+ T Cells**

Peter Fecci

9:00 - 9:15 **Discussion**

9:15 – 9:30 **Break**

Session 1

Session 1A: Targeting Brain Tumor Omics

Location: Grand Oaks A/B

9:30 - 9:35 **Introduction**

Moderators: Simon Gregory and Uri Tabori

9:35 - 9:42 **The Application of Leading-Edge Spatial Approaches Towards Understanding the Molecular Mechanisms Associated with Brain Tumor Development and Progression**

Simon Gregory

9:42 - 9:49 **Targeting Asparagine Metabolism for Treatment of Progressing Malignant Glioma**

Yuichi Hirose

9:49 - 9:56 **Targeting Cellular Plasticity-Driven Metabolic Adaptation to Overcome Chemoresistance in GBM**

Atique Ahmed

9:56 - 10:03 **Subgroup Specific Vulnerabilities and Responses to Immunotherapy of Replication Repair Hypermutant Gliomas. A Report from the International Replication Repair Deficiency Consortium (IRRDC)**

Uri Tabori

10:03 - 10:10 **The Cellular Selection Pressures of Standard Therapy in Glioblastoma**

Aaron Diaz

Wednesday, March 29, 2023

- 10:10 - 10:17 **PID1 Inhibits a Key Growth-Regulatory Pathway and is an Interacting Partner for a Kinase in IT**
Anat Erdreich-Epstein
- 10:17 - 10:24 **The Interplay of Methionine and Folate Metabolism with Epigenetics**
Sameer Agnihotri
- 10:24 - 10:31 **Spatial Heterogeneity in High Grade Glioma Drives an Altered Immune Microenvironment**
Saskia Freytag
- 10:31 - 10:46 **Discussion**

Session 1B: Tumor Immunology, Immunotherapy, and Biomarkers
Location: Grand Oaks C/D

- 9:30 - 9:35 **Introduction**
Moderators: Justin Lathia and Michael Lim
- 9:35 - 9:42 **Innate Immune Epigenetic Silencing in Glioblastoma: A Therapeutic Vulnerability and Clue to the Cell of Origin?**
David Ashley
- 9:42 - 9:49 **Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade**
Edjah Nduom
- 9:49 - 9:56 **Multidimensional Profiling of the T Cell Immunobiology in Glioblastoma Reveals a Distinct Signature of Immunomodulation**
Malte Mohme
- 9:56 - 10:03 **Interferon-Gamma Mediates Reprogramming of Innate Anti-Tumor Immunity in the Leptomeninges**
Adrienne Boire
- 10:03 - 10:10 **Sex-Specific Differences in Immune Response Underlie Disease Progression and Immunotherapy Responses in Glioblastoma**
Justin Lathia
- 10:10 - 10:17 **Novel SynNotch CAR T Cells with CNS-Specific Expression of CAR as a Safe and Effective Therapy for Glioblastoma**
Hideho Okada
- 10:17 - 10:24 **Genomic and Serologic Evaluation of Alzheimer's Disease Risk Factors in the Etiology of Glioblastoma**
Kyle Walsh

Wednesday, March 29, 2023

10:24 - 10:31 **Antibody Reactivity to VZV and EBV Improves Glioma Survival and is Modified by Germline HLA Polymorphisms**
Stephen Francis

10:31 – 10:46 **Discussion**

10:46 – 11:01 **Break**

Session 2

Session 2A: Oncolytic Viral Therapy

Location: Grand Oaks A/B

11:01 - 11:06 **Introduction**
Moderators: Matthias Gromeier and James Markert

11:06 - 11:13 **Zika Virus to Treat Glioblastoma**
Milan Chheda

11:13 - 11:20 **Engaging Conventional Dendritic Cells with Recombinant Poliovirus for Generating Durable Systemic Antitumor Immunity in the Brain**
Matthias Gromeier

11:20 - 11:27 **Recombinant Oncolytic Poliovirus (PVSRIPO) Therapy of Glioblastoma: A CNS Autopsy Study**
Roger McLendon

11:27 - 11:34 **Oncolytic Virotherapy for Glioma: The UAB Experience**
James Markert

11:34 - 11:41 **Translating the Delta-24 Platform to Pediatric Brain Tumors**
Marta Alonso

11:41 - 11:48 **New Insights on Innate Immune Pathways Sensing Oncolytic Adenoviruses**
Candelaria Gomez-Manzano

11:48 - 11:55 **Immune Tolerance for Viral Antigens Facilitates Tumoral Epitope Spreading During Oncolytic Virotherapy**
Juan Fueyo

11:55 - 12:02 **Impact of PKR on Oncolytic Virotherapy**
Balveen Kaur

12:09 – 12:25 **Discussion**

Wednesday, March 29, 2023

Session 2B: Novel Therapeutic Models
Location: Grand Oaks C/D

- 11:01 - 11:06 **Introduction**
Moderators: Peter Fecci and Aaron Diaz
- 11:06 - 11:13 **The Role of The Homeobox Transcription Factor DLX2 in Cell Fate Determination in Pediatric High-Grade Glioma**
David Eisenstat
- 11:13 - 11:20 **Systemic CCL3 Treatment Improves DC Vaccine Migration, Reduces T Cell Sequestration and Generates Efficacy Against Glioma**
Gary Archer
- 11:20 - 11:27 **Targeting Purine Metabolism with Mycophenolate Mofetil in Glioblastoma Patients to Overcome Chemoradiation Resistance**
Yoshie Umemura
- 11:27 - 11:34 **Human Plasma-Like Media Facilitates Metabolic Flux Tracing of Glioma and Upregulates Critical Gene Expression Networks**
Kalil Abdullah
- 11:34 - 11:41 **Integrated Molecular Analysis of IDH Mutant Gliomas Identifies Overexpression of Hox Genes as Poor Prognosticator**
Galereh Zadeh
- 11:41 - 11:48 **Intra-Arterial NEO100 Reversibly Opens the BBB for Car T-Cell Penetration to the Brain**
Thomas Chen
- 11:48 - 11:55 **Improved Delivery of Selumetinib and Everolimus to GBM Using Intrinsically Disordered Protein Surfactants**
Matthew Francis
- 11:55 - 12: 17 **Discussion**
- 12:25 – 12:35 **Closing Remarks by David Ashley, Masao Matsutani, and Koichi Ichimura**
Location: Grand Oaks A/B

Delegates

Kalil Abdullah, MD
University of Pittsburgh

Manish Aghi, MD, PhD
University of California, San Francisco

Sameer Agnihotri, PhD
University of Pittsburgh

Atique Ahmed, PhD
Northwestern University

Kenneth Aldape, MD
National Cancer Institute

Marta Alonso, PhD
University Clinic of Navarra

Gary Archer, PhD
Duke University

Hideyuki Arita, MD, PhD
Osaka International Cancer Institute

David Ashley, MBBS (Hon), FRACP, PhD
Duke University

Irina Balyasnikova, PhD
Northwestern University

Tracy Batchelor, MD, PhD
Brigham and Women's Hospital

Kristen Batich, MD
Duke University

Mitchel Berger, MD
University of California, San Francisco

Chetan Bettegowda, MD, PhD
Johns Hopkins University School of
Medicine

Rolf Bjerkvig, PhD
University of Bergen

Adrienne Boire, MD, PhD
Memorial Sloan Kettering Cancer Center

Priscilla Brastianos, MD
Massachusetts General Hospital

Daniel Cahill, MD, PhD
Massachusetts General Hospital

Maria Castro, PhD
University of Michigan

Vidyalakshmi Chandramohan, PhD
Duke University

Susan Chang, MD
University of California, San Francisco

Thomas Chen, MD, PhD
University of Southern California

Shiyuan Cheng, PhD
Northwestern University

Milan Chheda, MD
Washington University School of Medicine

E. Antonio Chiocca, MD, PhD, FAANS
Brigham and Women's Hospital

Elizabeth Claus, MD, PhD
Yale University

Timothy Cloughesy, MD
University of California, Los Angeles

Howard Colman, MD, PhD
Huntsman Cancer Institute, University of Utah

John de Groot, MD
University of California, San Francisco

Macarena De La Fuente, MD
University of Miami

Annick Desjardins, MD
Duke University

Girish Dhall, MD
The University of Alabama at Birmingham

Aaron Diaz, PhD
University of California, San Francisco

Charles Eberhart, MD, PhD
John's Hopkins University

David Eisenstat, MD, MA, FRCPC, FRACP
Royal Children's Hospital Melbourne

Benjamin Ellingson, PhD
University of California Los Angeles

Anat Erdreich-Epstein, MD, PhD
Children's Hospital Los Angeles

Peter Fecci, MD, PhD
Duke University

Jonathan Finlay, MB ChB, FRCP (Lond.), FRCPC
The Ohio State University College of Medicine

Matthew Francis, PhD
University of California, Berkeley

Stephen Francis, PhD, MS
University of California, San Francisco

Pim French, PhD
Erasmus MC

Saskia Freytag, PhD
Walter and Eliza Hall Institute of Medical Research

Juan Fueyo, MD
MD Anderson Cancer Center

Frank Furnari, PhD
University of California, San Diego

Candelaria Gomez-Manzano, MD
MD Anderson Cancer Center

Simon Gregory, PhD
Duke University

Matthias Gromeier, MD
Duke University

Rachel Grossman, MD
Tel Aviv University Sackler

Yiping He, PhD
Duke University

Dieter Henrik Heiland, MD
Neurosurgery Freiburg

Christel Herold-Mende, PhD
University of Heidelberg

Shawn Hervey-Jumper, MD
University of California, San Francisco

Yuichi Hirose, PhD
Fujita Health University

Craig Horbinski, MD, PhD
Northwestern University

Antonio Iavarone, MD
University of Miami Miller School of Medicine

Koichi Ichimura, MD, PhD
Juntendo University

Robert Jenkins, MD, PhD
Mayo Clinic

Randy Jensen, MD, PhD, MHPE
University of Utah

Seok-Gu Kang, MD, PhD
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Noriyuki Kasahara, MD, PhD
University of California, San Francisco

Balveen Kaur, PhD
Augusta University

Steve Keir, DrPH, MPH, MMCI
Duke University

Mustafa Khasraw, MBChB, MD, FRACP, FRCP
Duke University

Manabu Kinoshita, MD, PhD
Asahikawa Medical University

Cassie Kline, MD, MAS
Children's Hospital of Philadelphia

Takashi Komori, MD, PhD
Tokyo Metropolitan Neurological Hospital

Priya Kumthekar, MD
Northwestern University

Kazuhiko Kurozumi, MD, PhD
Hamamatsu University School of Medicine

Katrin Lamszus, MD
University Medical Center Hamburg-Eppendorf

Frederick Lang, MD
MD Anderson Cancer Center

Justin Lathia, PhD
Cleveland Clinic

Sean Lawler, PhD
Brown University

Michael Lim, MD
Stanford University School of Medicine

Giselle Lopez, MD, PhD
Duke University

Pedro Lowenstein, MD, PhD
University of Michigan

Janine Lupo, PhD
University of California, San Francisco

James Markert, MD, MPH
University of Alabama at Birmingham

Masao Matsutani, MD, PhD
Saitama Medical University

Samuel McBrayer, PhD
Children's Research Institute UT Southwestern

Roger McLendon, MD
Duke University

Shin-Ichi Miyatake, MD, PhD
Osaka Medical and Pharmaceutical University

Malte Mohme, MD
University Medical Center Hamburg-Eppendorf

Akitake Mukasa, MD, PhD
Kumamoto University

Motoo Nagane, MD, PhD
University Faculty of Medicine

Mitsutoshi Nakada, MD, PhD
Kanazawa University

Do-Hyun Nam, MD, PhD
Samsung Medical Center

Yoshitaka Narita, MD, PhD
National Cancer Center Hospital

MacLean Nasrallah, MD, PhD
Hospital of the University of Pennsylvania

David Nathanson, PhD
University of California, Los Angeles

Manabu Natsumeda, MD, PhD
Niigata University

Edjah Nduom, MD
Emory University School of Medicine

Theodore Nicolaides, MD
Caris Life Sciences

Ryo Nishikawa, MD
Nerima-station Rehabilitation Hospital

Masashi Nomura, MD, PhD
Massachusetts General Hospital

Hideho Okada, MD, PhD
University of California, San Francisco

Quinn Ostrom, PhD
Duke University

James Perry, MD FRCPC FAAN
University of Toronto

Katherine Peters, MD, PhD, FAAN
Duke University

Joanna Phillips, MD, PhD
University of California, San Francisco

Russell Pieper, PhD
University of California, San Francisco

Torsten Pietsch, MD
University of Bonn

Karl Plate, MD
Frankfurt University Hospital

Robert Prins, PhD
University of California, Los Angeles

Vinay Puduvalli, MD
MD Anderson Cancer Center

David Raleigh, MD, PhD
University of California, San Francisco

Zvi Ram, MD
Tel Aviv University Sackler School of Medicine

David Reardon, MD
Dana-Farber Cancer Institute

James Rutka, MD, PhD, FRCSC, FACS, FAANS
Sick Kids Hospital

Ryuta Saito, MD, PhD
Nagoya University

Nader Sanai, MD
Ivy Brain Tumor Center

Nils Ole Schmidt, MD
University Medical Center Regensburg

Dana Silverbush, PhD
Broad Institute of MIT and Harvard

David Solomon, MD, PhD
University of California, San Francisco

Yukihiko Sonoda, MD, PhD
Yamagata University

Erik Sulman, MD, PhD
NYU Grossman School of Medicine

Hiromichi Suzuki, MD, PhD
National Cancer Center Japan

Uri Tabori, MD
Hospital for Sick Children

Hirokazu Takami, MD, PhD
University of Tokyo Hospital

Keita Terashima, MD, PhD
National Center for Child Health and Development

Frits Thorsen, PhD
University of Bergen, Norway

Tomoki Todo, PhD
Institute of Medical Science, The University of Tokyo

Yoshie Umemura, MD
University of Michigan

Erwin Van Meir, PhD
University of Alabama at Birmingham

Andreas von Deimling, MD
University Hospital Heidelberg

Kyle Walsh, PhD
Duke University

William Weiss, MD, PhD
University of California, San Francisco

Patrick Wen, MD
Dana-Farber Cancer Institute

Bart Westerman, PhD
Amsterdam UMC, Cancer Center Amsterdam CCA,
Brain Tumor Center Amsterdam

Manfred Westphal, MD
University Clinic Hamburg-Eppendorf

James Whittle, MD, PhD
Walter and Eliza Hall Institute of Medical Research

Koji Yoshimoto, MD, PhD
Kyushu University

W.K. Alfred Yung, MD

MD Anderson Cancer Center

Gelareh Zadeh, MD, PhD, FRCSC

University of Toronto

Marc Zuckermann, PhD

German Cancer Research Center